N	Concordance
1	was not agonistic alone and antagonized estrogen action. In contrast, the three 
2	ew studies have examined the effects of estrogen administration in conjunction w
3	 antiestrogen, OH-tamoxifen into a full estrogen agonist, we transfected this mu
4	mastia, leading all to an increased net estrogen/androgen ratio that effectively
5	tion to an elevation of nuclear type II estrogen binding sites (type II EBS), no
6	 cancer model for testing inhibitors of estrogen biosynthesis and its action usi
7	of tumor angiogenesis induction, during estrogen carcinogenesis, are still unkno
8	tor through the screening of agents for estrogen-dependent breast cancer. SEF19 
9	well as the long-term health effects of estrogen deprivation after ovarian remov
10	onatal exposure to the potent synthetic estrogen diethylstilbestrol (DES). Norma
11	om female-to-male trans-sexuals than in estrogen-dominant FF, whereas IGF-II lev
12	 combination oral contraceptives (OCs), estrogen dose, cigarette smoking, and th
13	ituitary cells, suggests a "functional" estrogen-induced hyperprolactinemia. Bro
14	 etrial cancer associated with elevated estrogen levels and decreased risks asso
15	rogens to understand the differences in estrogen metabolism in these organs. In 
16	ys that progestin is used in sequential estrogen-progestin replacement therapy. 
17	aloxifene (LY139481 HCl) is a selective estrogen receptor modulator (SERM) which
18	ontrol report of an association between estrogen replacement therapy and endomet
19	 of reporter gene constructs containing estrogen-response elements in transient 
20	ts suggest a mechanism by which chronic estrogen treatment of osteoblasts affect